---
document_datetime: 2025-12-02 05:03:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/syfovre.html
document_name: syfovre.html
version: success
processing_time: 0.0676405
conversion_datetime: 2025-12-28 15:14:48.308387
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Syfovre

[RSS](/en/individual-human-medicine.xml/230712)

##### Refused

This medicine has been refused authorisation

pegcetacoplan Medicine Human Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Syfovre](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The company that applied for marketing authorisation, Apellis Europe B.V., had requested re-examination of EMA's initial opinion of 27 June 2024 recommending the refusal of the marketing authorisation for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration (AMD).

After re-examining its initial opinion, the European Medicines Agency issued its final opinion on 19 September 2024 in which it confirmed its recommendation to refuse marketing authorisation for Syfovre.

Expand section

Collapse section

## What is Syfovre and what was it intended to be used for?

Syfovre was developed as a medicine to treat adults with geographic atrophy, an advanced form of AMD. AMD is a disease that affects the central part of the retina (called the macula) at the back of the eye. In patients with geographic atrophy, lesions (areas of cell death) develop in the retina and macula, leading to loss of vision. Syfovre contains the active substance pegcetacoplan and was to be available as a solution to be injected into the eye.

## How does Syfovre work?

The complement system is a set of proteins that is part of the immune system (the body's natural defences). In people with geographic atrophy, the complement system is overactive, causing inflammation and cell death. The active substance in Syfovre, pegcetacoplan, attaches to and blocks the C3 protein of the complement system. By blocking C3, pegcetacoplan prevents activation of the complement system. This slows down the growth of geographic atrophy lesions.

## What did the company present to support its application?

The company presented results from two main studies involving a total of 1,258 adults with geographic atrophy caused by AMD. The studies lasted 24 months and compared Syfovre injections into the eye with a sham procedure where no actual injection was given. The main measure of effectiveness was the change in the size of geographic atrophy lesions in the eye after 12 months.

## What were the main reasons for refusing the marketing authorisation?

At the time of the initial evaluation, although the studies showed that Syfovre slowed the growth of geographic atrophy lesions, the Agency considered that this did not lead to clinically meaningful benefits for patients. It was noted that benefits of a treatment should have an impact on patients' everyday functioning, and this was not demonstrated in the studies. In terms of safety, regular injections into the eye carry a significant risk of adverse events, including the development of other forms of AMD or inflammation in the eye, which could further worsen vision.

These concerns did not change after re-examination of the data provided and consideration of information shared by patients and healthcare professional organisations (so-called third-party interventions). Although the Agency recognises the unmet medical need for effective treatment for people with geographic atrophy caused by AMD, its opinion remained that the magnitude of Syfovre's effectiveness did not outweigh the potential risks. The Agency therefore concluded that a positive balance of the medicine's benefits and risks could not be established in the treatment of geographic atrophy caused by AMD.

## Does this refusal affect patients in clinical trials?

The company informed the Agency that there are no consequences for patients in clinical trials with Syfovre.

If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

Questions and answers on the refusal of the marketing authorisation for Syfovre (pegcetacoplan)

Reference Number: EMA/432931/2024

English (EN) (113.34 KB - PDF)

**First published:** 10/10/2025

**Last updated:** 30/10/2025

[View](/en/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_en.pdf)

[Other languages (22)](#file-language-dropdown-32)

български (BG) (135.88 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/bg/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_bg.pdf)

español (ES) (112.25 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/es/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_es.pdf)

čeština (CS) (132.55 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/cs/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_cs.pdf)

dansk (DA) (112.89 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/da/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_da.pdf)

Deutsch (DE) (116.11 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/de/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_de.pdf)

eesti keel (ET) (111.5 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/et/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_et.pdf)

ελληνικά (EL) (135.26 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/el/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_el.pdf)

français (FR) (113.89 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/fr/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_fr.pdf)

hrvatski (HR) (133.97 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/hr/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_hr.pdf)

italiano (IT) (111.68 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/it/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_it.pdf)

latviešu valoda (LV) (130.71 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/lv/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_lv.pdf)

lietuvių kalba (LT) (133.99 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/lt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_lt.pdf)

magyar (HU) (134.76 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/hu/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_hu.pdf)

Malti (MT) (136.62 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/mt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_mt.pdf)

Nederlands (NL) (113.05 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/nl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_nl.pdf)

polski (PL) (136.19 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/pl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_pl.pdf)

português (PT) (113.49 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/pt/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_pt.pdf)

română (RO) (131.15 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/ro/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_ro.pdf)

slovenčina (SK) (134.41 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/sk/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_sk.pdf)

slovenščina (SL) (132.27 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/sl/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_sl.pdf)

Suomi (FI) (110.98 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/fi/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_fi.pdf)

svenska (SV) (112.3 KB - PDF)

**First published:**

10/10/2025

**Last updated:**

30/10/2025

[View](/sv/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-syfovre-pegcetacoplan_sv.pdf)

## Product details

Name of medicine Syfovre International non-proprietary name (INN) or common name pegcetacoplan Therapeutic area (MeSH)

- Macular Degeneration
- Geographic Atrophy

Anatomical therapeutic chemical (ATC) code S01XA31

### Pharmacotherapeutic group

Ophthalmologicals

## Application details

EMA product number EMEA/H/C/005954 Marketing authorisation applicant Apellis Europe B.V. Opinion adopted 19/09/2024 Opinion status Negative Refusal of marketing authorisation 16/12/2024

## Assessment history

Syfovre : EPAR - Refusal public assessment report

Adopted

Reference Number: EMA/CHMP/196327/2025 Corr.

English (EN) (14.54 MB - PDF)

**First published:** 14/08/2025

**Last updated:** 10/10/2025

[View](/en/documents/assessment-report/syfovre-epar-refusal-public-assessment-report_en.pdf)

#### News on Syfovre

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2024) 20/09/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024) 26/04/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/10/2025

## Share this page

[Back to top](#main-content)